Sugi Predict

Sugi Predict / Compounds / SCHEMBL994316

SCHEMBL994316

SCHEMBL994316

CC(C)(C)OC(=O)N1CCC(N2CCC2=O)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ FPR2 P25090 1/20 0.47
▸ GPR119 Q8TDV5 4/20 0.47
▸ RECQL P46063 1/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ PTPN2 P17706 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PTPN6 P29350 1/20 0.46
▸ DDB1 Q16531 2/20 0.45
▸ CRBN Q96SW2 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ CTSD P07339 1/20 0.44
▸ CTSE P14091 1/20 0.44
▸ BACE1 P56817 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22720456 0.91 HPGD (0.50) TP53KDM4EMAPTTHRBHPGD
SCHEMBL1976724 0.90 HPGD (0.52) TP53KDM4EMAPTTHRBHPGD
SCHEMBL22999786 0.89 TP53 (0.47) TP53KDM4EMAPTTHRBHPGD
SCHEMBL16992349 0.89 HPGD (0.55) TP53KDM4EMAPTTHRBHPGD
SCHEMBL19188152 0.87 EPHX1 (0.47) TP53KDM4EMAPTTHRBHPGD
SCHEMBL14335350 0.85 DDB1 (0.46) TP53KDM4EMAPTTHRBHPGD
SCHEMBL16992253 0.83 MAPT (0.50) TP53KDM4EMAPTTHRBHPGD
SCHEMBL22720469 0.83 TP53 (0.53) TP53KDM4EMAPTTHRBHPGD
SCHEMBL21201857 0.83 VNN1 (0.50) TP53KDM4EMAPTTHRBHPGD
SCHEMBL15491802 0.82 HPGD (0.48) TP53KDM4EMAPTTHRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024499-B2 Muscarinic agonists HEPTARES THERAPEUTICS LIMITED (GB) 2024-07-02 — — US disclosed
US-12024499-B2 Muscarinic agonists HEPTARES THERAPEUTICS LIMITED (GB) 2024-07-02 — — US disclosed
US-12024499-B2 Muscarinic agonists HEPTARES THERAPEUTICS LIMITED (GB) 2024-07-02 — — US disclosed
US-20230002354-A1 MUSCARINIC AGONISTS NXERA PHARMA UK LIMITED (GB) 2023-01-05 — — US disclosed
US-20230002354-A1 MUSCARINIC AGONISTS NXERA PHARMA UK LIMITED (GB) 2023-01-05 — — US disclosed
US-11254656-B2 Muscarinic agonists HEPTARES THERAPEUTICS LIMITED (GB) 2022-02-22 — — US disclosed
US-11254656-B2 Muscarinic agonists HEPTARES THERAPEUTICS LIMITED (GB) 2022-02-22 — — US disclosed
EP-3331529-B1 MUSCARINIC AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-09-29 — — EP disclosed
EP-3331529-B1 MUSCARINIC AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-09-29 — — EP disclosed
CN-108025004-B Muscarinic agonists 赫普泰雅治疗有限公司 2021-07-09 — — CN disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 — — US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 — — US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 — — US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 — — US disclosed
EP-2215090-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-08-11 — — EP disclosed
EP-2205610-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 — — EP disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
WO-2009053716-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
WO-2009053716-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS PIK3CA, PIK3CD, PI4KA TP53 889/4885KDM4E 3891/4885MAPT 4128/4885
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS PIK3CA, PIK3CD, PIK3CB TP53 351/4885KDM4E 1577/4885MAPT 2849/4885
US-20230002354-A1 MUSCARINIC AGONISTS CHRM1, CHRM2, CHRM3 TP53 2034/4885KDM4E 3054/4885MAPT 2003/4885
US-11254656-B2 Muscarinic agonists CHRM1, CHRM2, CHRM3 TP53 2034/4885KDM4E 3054/4885MAPT 2003/4885
US-12024499-B2 Muscarinic agonists CHRM1, CHRM2, CHRM3 TP53 2034/4885KDM4E 3054/4885MAPT 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.